Table 3.

Risk of site-specific cancers following BCC, SCC, NMSC, and males and females among registry-based studies

Site of second primary cancer	NMSC SRR (95% CI) *	NMSC: Males SRR (95% CI) *	NMSC: Females SRR (95% CI) *	BCC SRR (95% CI) *	SCC SRR (95% CI) *
Lung	1.23 (1.13 – 1.33)	1.27 (1.16 – 1.39)	1.19 (1.06 – 1.33)	1.13 (1.01 – 1.27)	1.34 (1.22 – 1.47)
Breast	1.04 (0.96 – 1.14)	-- †	1.04 (0.96 – 1.14)	1.08 (0.99 – 1.19)	0.97 (0.88 – 1.08)
Colorectal	1.05 (0.97 – 1.13)	1.05 (0.95 – 1.16)	1.03 (0.94 – 1.13)	1.02 (0.93 – 1.13)	1.03 (0.93 – 1.15)
Melanoma	2.74 (2.49 – 3.02)	2.73 (2.52 – 2.96)	2.61 (2.24 – 3.05)	2.75 (2.39 – 3.16)	2.84 (2.45 – 3.29)
Pancreas	0.94 (0.82 – 1.07)	1.07 (0.97 – 1.18)	0.91 (0.78 – 1.06)	-- ‡	-- ‡
Leukemia	1.26 (1.04 – 1.52)	1.45 (1.17 – 1.79)	1.24 (0.99 – 1.55)	1.12 (0.93 – 1.35)	1.45 (0.93 – 2.11)
Cervix	0.93 (0.62 – 1.41)	-- †	0.93 (0.62 – 1.41)	0.84 (0.50 – 1.41)	-- ‡
Non-Hodgkin lymphoma	1.58 (1.37 – 1.81)	1.56 (1.33 – 1.84)	1.58 (1.37 – 1.82)	1.39 (1.22 – 1.58)	2.00 (1.80 – 2.22)
Myeloma	1.18 (1.06 – 1.32)	-- ‡	-- ‡	-- ‡	-- ‡
Salivary Gland	4.57 (2.92 – 7.15)	5.22 (3.32 – 8.22)	3.65 (1.91 – 6.95)	-- ‡	7.15 (4.09 – 12.52)
Thyroid	1.28 (0.95 – 1.71)	1.72 (0.55 – 5.33)	1.23 (0.99 – 1.53)	1.24 (0.92 – 1.67)	-- ‡
Prostate	1.04 (0.98 – 1.12)	1.04 (0.98 – 1.12)	-- †	1.07 (0.97 – 1.17)	1.00 (0.94 – 1.07)
Lip	2.38 (2.03 – 2.79)	2.09 (1.88 – 2.31)	4.45 (2.76 – 7.19)	-- ‡	3.79 (3.15 – 4.57)
Mouth and pharynx	1.69 (1.31 – 2.18)	1.94 (1.50 – 2.49)	1.87 (1.26 – 2.78)	1.32 (1.13 – 1.55)	2.05 (1.33 – 3.19)
Esophagus	1.06 (0.85 – 1.32)	1.15 (0.92 – 1.45)	1.11 (0.90 – 1.36)	0.90 (0.67 – 1.21)	1.21 (0.83 – 1.74)

^*Summary relative risk and 95% confidence interval

^†Not applicable

^‡Relative risk estimate presented in fewer than 5 studies